Clinical efficacy and safety in patients treated with teicoplanin with a target trough concentration of 20 μg/mL using a regimen of 12 mg/kg for five doses within the initial 3 days

• Main Authors: Takashi Ueda (Author), Yoshio Takesue (Author), Kazuhiko Nakajima (Author), Kaoru Ichiki (Author), Kaori Ishikawa (Author), Yoshiko Takai (Author), Kumiko Yamada (Author), Toshie Tsuchida (Author), Naruhito Otani (Author), Yoshiko Takahashi (Author), Mika Ishihara (Author), Shingo Takubo (Author), Hiroki Ikeuchi (Author), Motoi Uchino (Author), Takeshi Kimura (Author)
• Format: Book
• Published: BMC, 2020-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background A trough concentration (Cmin) ≥20 μg/mL of teicoplanin is recommended for the treatment of serious methicillin-resistant Staphylococcus aureus (MRSA) infections. However, sufficient clinical evidence to support the efficacy of this target Cmin has not been obtained. Even though t...